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Background
Being a disabling symptom of many medical conditions,
effective pain control is one of the most important ther-
apeutic priorities. Morphine and other opioid drugs pro-
duce analgesia primarily through μ opioid (MOP)
receptors, which mediate beneficial but also the non-
beneficial actions. Appropriate identification of novel
opioid analgesics may reduce complications and improve
patient compliance. It was reported that hydrazones,
oximes, carbazones and semicarbazone derivatives of
morphinan-6-ones, e.g. dihydromorphinone or oxymor-
phone, exhibit high affinity at the MOP receptor [1].
Since most of these structures show high antinociceptive
potency while having less pronounced side effects, it
remains a promising task to convert the carbonyl group
of morphinan-6-ones into various functionalities. In this
study, we aimed to investigate the effect of the replace-
ment of the 6-keto function with a 6-cyano group on
in vitro and in vivo pharmacological profiles.
Methods
Binding affinities at opioid receptors were determined
using competition binding assays in rodent brain mem-
branes. In vitro [
35S]GTPgS functional assays were
performed with Chinese hamster ovary (CHO) cell
membranes expressing human opioid receptors. Antino-
ciceptive activities were assessed in mice using tail-flick,
hot-plate and writhing tests.
Results
Replacement of the 6-keto group by a 6-cyano substituent
in N-methylmorphinan-6-ones leads to qualitative and
quantitative differences in the interaction with opioid
receptors. Consequently, we have conducted a comparison
of the biological activities of the 6-cyanomorphinans to
those of structurally-related opioids, oxycodone, oxymor-
phone and of the clinically relevant morphine. The 6-cya-
nomorphinans displayed high affinity and behaved as
agonists at the MOP receptor. When tested in vivo,t h e y
acted as potent antinociceptive agents after subcutaneous
administration, being more active than the 6-keto analo-
gues. The presence of a 14-methoxy or a 14-cinnamyloxy
group instead of a hydroxy group not only increased
in vitro opioid activity at the MOP receptor, but also
enhanced the antinociceptive potency.
Conclusions
Our findings revealed that targeting position 6 in the
morphinan skeleton represents a viable approach for
tuning the pharmacological properties of this class of
opioids. Appropriate molecular manipulations could
afford ligands that, besides their scientific value as phar-
macological tools, may also have the potential of emer-
ging as novel analgesics with fewer side effects
compared to currently available treatments.
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